Background-Despite the therapeutic potential of endothelial progenitor cells (EPCs) in ischemic vascular diseases, their insufficient numbers limit clinical applications. Peroxisome proliferator-activated receptor (PPAR)-␦ belongs to the nuclear hormone receptor superfamily, and its functions in various tissues and cells are almost unexplored, especially with respect to vascular biology. Methods and Results-PPAR-␦ activation in EPCs phosphorylated Akt, and this phosphorylation was mediated not only by genomic but also by nongenomic pathways through interaction with the regulatory subunit of phosphatidylinositol 3-kinase. PPAR-␦ activation with agonist (GW501516 or L-165041) increased the proliferation of human EPCs and protected them from hypoxia-induced apoptosis. In addition, PPAR-␦ activation enhanced EPC functions, such as transendothelial migration, and tube formation. These actions by PPAR-␦ activation in EPCs were dependent on the phosphatidylinositol 3-kinase/Akt pathway. In ischemic hindlimb of mice models, transplantation of PPAR-␦ agonist-treated human or mouse EPCs enhanced blood flow recovery to ischemic limbs compared with vehicle-treated EPCs. In EPCs from PPAR-␦-knockout mice, however, treatment with PPAR-␦ agonist did not enhance in vivo vasculogenic potential. Systemic administration of PPAR-␦ agonist increased hematopoietic stem cells in bone marrow and EPCs in peripheral blood, leading to improved vasculogenesis with incorporation of bone marrow-derived cells to new vessels in a corneal neovascularization model and limb salvage with better blood flow in an ischemic hindlimb model. Conclusions-The results of our study suggest that PPAR-␦ agonist has therapeutic vasculogenic potential for the treatment of ischemic cardiovascular diseases.
ily. 3 Three isoforms have been identified thus far, ie, PPAR-␣, PPAR-␥, and PPAR-␦. Recent data have implicated PPAR-␥ ligands in angiogenesis modulation 4 and EPC biology. 5 Most studies conducted on the topic have concluded that PPAR-␥ activation inhibits angiogenesis. 4 Therefore, PPAR-␥ modulation may be a therapeutic target in numerous pathologies involving excessive angiogenesis, such as cancer. 6 By contrast, because of its ubiquitous expression and the delayed development of selective ligands, PPAR-␦ is the least understood PPAR subtype. 7 Most studies have associated PPAR-␦ activation with its metabolic effects. Interestingly, some evidence indicates that the activation of PPAR-␦ stimulates angiogenesis. PPAR-␦ activation was shown to induce the proliferation of endothelial cells (ECs) 8, 9 and protect them from apoptosis. 10 However, few studies have systematically evaluated the implications of PPAR-␦ activation in vascular biology. In particular, the role of PPAR-␦ in vasculogenesis and its effect on EPCs are virtually unknown.
Thus, in the present study, we studied the effects of PPAR-␦ activation on the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway in detail and showed that both genomic and nongenomic activations occurred. Next, we evaluated the proliferation, apoptosis, and various functions of EPCs after PPAR-␦ activation. Finally, the in vivo effect of PPAR-␦ activation was also investigated in 2 ways, ie, local delivery of agonist-treated EPCs and systemic administration of agonist.
Methods
Expanded methods are available in the online-only Data Supplement.
Cell Culture
All human aspects of this study were approved by the institutional review board of Seoul National University Hospital. For early EPC cultures, 50 mL of peripheral blood was obtained from healthy volunteers with informed consent. The mononuclear cells (MNCs) were fractionated with Ficoll as described previously, 11, 12 and isolated MNCs were resuspended with the use of an EGM-2MV BulletKit system (Clonetics) consisting of endothelial basal medium, 5% fetal bovine serum (FBS), human epidermal growth factor, vascular endothelial growth factor, human fibroblast growth factor-B, insulin-like growth factor-1, ascorbic acid, and heparin; 1ϫ10 7 MNCs per well were seeded on 2% fibronectin-coated (Sigma, St Louis, Mo) 6-well plates and incubated in a 5% CO 2 incubator at 37°C.
Trypan Blue Exclusion Assay
Isolated MNCs were cultured for 5 days in EGM-2MV, which was then changed to EBM-2 (Clonetics) with FBS 5%. EPCs were treated with PPAR-␦ agonists (GW501516 [Alexis], L-165041 [Sigma]) or vehicle for the whole culture period. At day 8, EPCs were harvested. Cells suspensions were mixed with the same volume of trypan blue, and the numbers of stained and unstained cells were counted over 3 randomly selected high-power fields.
Fluorescence-Activated Cell Sorter Analysis
Cell-cycle status and apoptosis were evaluated by flow cytometry, as described previously. 13 For cell-cycle progression analysis, isolated MNCs were cultured for 5 days in EGM-2MV with PPAR-␦ agonists or vehicle. Then adherent cells were harvested.
For analysis of apoptosis, isolated MNCs were cultured in EGM-2MV for 8 days, and the cultured EPCs were treated with PPAR-␦ agonists or vehicle in EBM-2 containing FBS 5% for 10 hours. Treated EPCs were subjected to hypoxia (an oxygen concentration of Ͻ2%) for 24 hours with the use of the GasPak pouch system (Becton-Dickinson) and then were harvested.
Transendothelial Migration Assay
EPCs were pretreated with PPAR-␦ agonists or vehicle under EBM-2 plus FBS 5% for 48 hours. Human gastroepiploic artery endothelial cells were grown on 8-m microporous membranes in transwell chambers. EPCs labeled with carboxyfluorescein succinimidyl ester (CFSE) (Sigma) (1ϫ10 5 /well) were added above GEAEC monolayers on the filters. Then the transwells were placed into a 24-well plate containing EGM-2MV as chemoattractant. After 6 hours of incubation, CFSE-tagged EPCs were counted over 3 randomly selected high-power fields in lower chambers.
Matrigel Tube Formation Assay
EPCs were pretreated with PPAR-␦ agonists or vehicle under EBM-2 plus FBS 5% for 48 hours. Growth factor-reduced Matrigel (BectonDickinson) was thawed and placed in chamber slides. EPCs (1ϫ10 5 ) were coplated with (2ϫ10 4 ) human umbilical vein ECs and incubated at 37°C for 12 hours. Four representative fields were taken, and the averages of the total areas and lengths of complete tubes per unit area were compared with the use of Image-Pro Plus.
Statistical Analysis
All data are presented as meanϮSEM. Student t test or 1-way ANOVA was performed for intergroup comparisons. Data taken at different time points were analyzed by repeated-measures ANOVA. SPSS version 12.0 was used for analysis, and a P value of Ͻ0.05 was considered statistically significant.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results

PPAR-␦ Agonist Induces Akt Phosphorylation in Human EPCs
The signaling pathway underlying PPAR-␦ activation in EPCs was investigated by Western blot analysis. We focused on the PI3K/Akt pathway because PPAR-␦ activation was shown to be associated with Akt phosphorylation in other cell types. 14, 15 In EPCs, the addition of GW501516 (1 mol/L), a potent and highly selective PPAR-␦ agonist, led to a significant increase in serine 473 Akt phosphorylation, reaching a peak at Ϸ8 hours ( Figure 1A ) while having no effects on total Akt.
GW501516 Activates PI3K/Akt Signaling via Genomic and Nongenomic Pathways
Akt Activation by GW501516 Is PPAR-␦ Dependent The so-called PPAR-␥ agonists are also known to exert PPAR-␥-independent effects. 16, 17 To test whether the activation of Akt by GW501516 is dependent on PPAR-␦, PPAR-␦ sense and antisense oligodeoxynucleotides were transfected into EPCs with the use of Oligofectamine. The PPAR-␦ antisense oligodeoxynucleotide transfection almost completely blocked PPAR-␦ mRNA and protein expression specifically ( Figure 1B) . When PPAR-␦ antisense oligodeoxynucleotide was transfected, Akt phosphorylation after 8 hours of GW501516 (1 mol/L) treatment was not observed ( Figure 1C ), suggesting that the activation of Akt by GW501516 occurs through a PPAR-␦-dependent pathway.
Akt Activation by GW501516 Is Mediated via Genomic Transcription
PPAR-␦ is a transcription factor itself. Pretreatment of EPCs with actinomycin D, a transcription inhibitor, for 1 hour abolished Akt phosphorylation after 8 hours of GW501516 (1 mol/L) treatment, suggesting that Akt phosphorylation by PPAR-␦ activation occurs via gene transcription. LY-294002, a PI3K inhibitor, pretreatment for 1 hour also diminished Akt phosphorylation, demonstrating that PPAR-␦ activation phosphorylates Akt through PI3K ( Figure 1D ). Neither LY-294002 nor actinomycin D treatment affected EPC viability in the usual culture condition as measured by the trypan blue exclusion assay (data not shown).
GW501516 Also Activates PI3K/Akt via a Nongenomic Pathway Through Interaction With a Regulatory Subunit of PI3K
Previous reports have suggested that mechanisms of nuclear receptor interaction exist at different levels of the signaling pathway, including receptor associations with several transcription factors or other components of the signaling system located at the cell membrane. 18 Interestingly, in pilot experiments to detect the time-dependent changes in Akt phosphorylation by GW501516, we noted that the early peak of Akt phosphorylation at serine 473 had occurred as early as Ͻ1 hour after GW501516 treatment ( Figure 2A ). The phosphorylation of Akt during the early period began within minutes and peaked at 10 minutes. The early phosphorylation of Akt also appeared to be PPAR-␦ dependent because PPAR-␦ antisense oligodeoxynucleotide transfection blocked Akt phosphorylation after 10 minutes of GW501516 (1 mol/L) treatment ( Figure 2B ). However, this early change in Akt phosphorylation did not seem to be a genomic effect of GW501516 because a change within 10 minutes is too early to be mediated by gene transcription and because the early phosphorylation was preserved despite actinomycin D pretreatment. However, LY-294002 abolished Akt phosphorylation after 10 minutes of GW501516 treatment (1 mol/L) ( Figure 2C ). Taken together, the aforementioned data suggest that Akt activation within 10 minutes after GW501516 treatment is a nongenomic effect mediated via PI3K.
Because a previous report showed that nuclear hormone receptors can directly bind to a regulatory subunit to activate PI3K, 19, 20 we tested whether the PPAR-␦ receptor also directly interacts with p85␣, a regulatory subunit of PI3K. An immunoprecipitation assay showed binding of PPAR-␦ to the p85␣ subunit of PI3K in a ligand-dependent manner, suggesting that the early peak in Akt activation may be due to a nongenomic direct interaction between PPAR-␦ and p85␣ ( Figure 2D ).
These activation mechanisms of the PI3K/Akt pathway by PPAR-␦ are depicted in Figure I in the online-only Data Supplement.
PPAR-␦ Agonist Increases the Number of EPCs and Protects EPCs From Hypoxia-Induced Apoptosis
The activation of the PI3K/Akt signaling pathway is known to promote EC survival 21 and angiogenesis. 22 In addition, we and others have demonstrated that it is also associated with EPC mobilization and vasculogenesis. [23] [24] [25] Thus, the potential of PPAR-␦ activation to modulate EPC biology was evaluated.
Trypan blue exclusion assays were performed to quantify the effect of GW501516 on the number of viable EPCs. MNCs were incubated with various concentrations of GW501516 for 8 days. At these concentrations, GW501516 is known to selectively activate only the PPAR-␦ receptor with 1000-fold selectivity over the other PPAR subtypes 26, 27 and not to affect any other nuclear or nonnuclear receptors. 26 In addition, under oral administration, the serum concentration of GW501516 can reach up to 1 mol/L in monkeys. 26 GW501516 significantly increased the number of viable EPCs dose dependently, which was reversed by LY-294002 (1 mol/L) (relative percentage to vehicle [100%]: 118.1Ϯ3.2%, 124.0Ϯ8.8%, 138.7Ϯ12.5%, and 115Ϯ6.4% for GW501516 100 nmol/L, 500 nmol/L, 1 mol/L, and 1 mol/LϩLY-294002, respectively) ( Figure 3A, 3B) .
To evaluate whether this increase of cell number was due to proliferation, the cell cycle was analyzed in 5-day cultured EPCs that had been incubated under GW501516 after MNC isolation. GW501516 significantly increased the number of EPCs in the S phase, which was reversed again by LY-294002 pretreatment (relative percentage to vehicle [100%]: 123.5Ϯ18.7%, 150.5Ϯ15.3%, 171.2Ϯ19.2%, and 122.6Ϯ 13.7% for GW501516 100 nmol/L, 500 nmol/L, 1 mol/L, and 1 mol/LϩLY-294002, respectively) ( Figure 3C) .
Next, the effect of PPAR-␦ activation on apoptosis of EPCs was tested. EPCs were treated with GW501516 and then exposed to hypoxia. After 24 hours, the subdiploid cell fraction, indicative of cells with DNA fragmentation during apoptosis, was decreased in cells treated with GW501516, which was reversed by LY-294002 (percentage of apoptotic cells: 23.6Ϯ2.0% versus 19.6Ϯ2.0%, 18.5Ϯ1.5%, 10.9Ϯ 0.6%, and 27.8Ϯ2.0% for vehicle versus GW501516 100 nmol/L, 500 nmol/L, 1 mol/L, and 1 mol/LϩLY-294002, respectively), suggesting protection of EPCs from hypoxiainduced apoptosis by GW501516 (Figure 3D, 3E) .
Another PPAR-␦ agonist, L-165041, which has been used to activate PPAR-␦ in several studies, 14,28 also induced proliferation of EPCs and protected them from apoptosis ( Figure IIA to IIE in the online-only Data Supplement).
PPAR-␦ Agonist Enhances EPC Function
The effects of PPAR-␦ activation on EPC function were assessed by measuring transendothelial migration and in vitro tube formation. CFSE-tagged EPCs treated with GW501516 for 48 hours were placed on a chamber on top of a microporous membrane layered with human gastroepiploic artery endothelial cells, and 6 hours later, the number of CFSE-tagged EPCs that migrated to the lower chamber was counted. GW501516 increased transendothelial migration of EPCs (relative percentage to vehicle [100%]: 110.9Ϯ13.3%, 128.9Ϯ11.2%, 151.6Ϯ 13.6%, and 101.9Ϯ7.5% for GW501516 100 nmol/L, 500 nmol/L, 1 mol/L, and 1 mol/LϩLY-294002, respectively) ( Figure 4A, 4B) .
In vitro tube formation by EPCs was measured with the use of a Matrigel network formation assay. Naive human umbilical vein ECs were cocultured on Matrigel with EPCs treated with GW501516. After 12 hours, the area and length of complete tubes were analyzed. GW501516-treated EPCs induced a significantly larger area (relative percentage to vehicle [100%]: 288.3Ϯ18.2%, 324.1Ϯ47.0%, 320.7Ϯ 11.6%, and 147Ϯ25.0% for GW501516 100 nmol/L, 500 nmol/L, 1 mol/L, and 1 mol/LϩLY-294002, respectively) and longer length of complete tubes (relative percentage to vehicle [100%]: 183.8Ϯ3.6%, 218.2Ϯ10.2%, 238.9Ϯ7.2%, and 122Ϯ16.2% for GW501516 100 nmol/L, 500 nmol/L, 1 mol/L, and 1 mol/LϩLY-294002, respectively) ( Figure  4C, 4D) .
The augmented migration and tube formation by EPCs treated with GW501516 (1 mol/L) were all reversed by LY-294002 (1 mol/L) pretreatment ( Figure 4A to 4D) , suggesting that these effects are mediated via the PI3K/Akt pathway. LY-294002 treatment did not affect EPC viability as measured by the trypan blue exclusion assay (data not shown).
L-165041 also enhanced EPC functions such as transendothelial migration and in vitro tube formation ( Figure IIIA to IIID in the online-only Data Supplement), suggesting that these effects are dependent on PPAR-␦ activation and not specific to GW501516.
Local Transplantation of PPAR-␦-Activated EPCs Enhances Vasculogenesis in Mouse Ischemic Hindlimb
To assess the impact of PPAR-␦ activation on EPCs in vivo, injection of GW501516-treated human EPCs was performed in hindlimb ischemia model of athymic nude mice. After unilateral femoral artery excision, athymic nude mice received either GW501516-or vehicle-treated human EPCs (nϭ12 in each group) labeled with 1,1Ј-dioctadecyl-3,3,3Ј3Ј-tetramethylindocarbocyanine perchlorate (DiI) via direct muscular injection. Quantitative analysis with the use of a laser Doppler perfusion imager confirmed significantly accelerated limb perfusion improvement throughout the 21-day follow-up period in the hindlimbs injected with the GW501516-treated EPCs ( Figure 5A , 5B). Histological examination of skeletal muscle of ischemic limb at day 21 showed significantly increased capillary density in mice transplanted with GW501516-treated EPCs (capillary density, 541.0Ϯ93.3/mm 2 versus 302.8Ϯ35.5/mm 2 for mice receiving GW501516-treated EPCs versus control EPCs) (Figure 5C, 5D) . A greater number of human DiI-labeled EPCs was detected in the ischemic limb of mice given GW501516-treated EPCs (human EPC density, 70.8Ϯ9.3/mm 2 versus 47.9Ϯ4.8/mm 2 for mice receiving GW501516-treated EPCs versus control EPCs) ( Figure 5C , 5E). These data suggest that ex vivo activation of PPAR-␦ in EPCs results in enhanced vasculogenic potential in vivo.
To test whether this in vivo provasculogenic effect of GW501516 is dependent on PPAR-␦, PPAR-␦-knockout (KO) mice were used. Mouse EPCs from PPAR-␦ KO or wild-type (WT) mice were cultured with GW501516 or vehicle and injected intramuscularly to the ischemic hindlimb. Blood flow recovery was significantly augmented by GW501516 pretreatment of transplanted EPCs from WT mice, whereas it was not from PPAR-␦ KO mice ( Figure  IVA , IVB in the online-only Data Supplement). In histological examination at day 21, higher capillary density and more accumulation of mouse EPCs were observed only in mice receiving GW501516-treated WT mouse EPCs but not in mice receiving GW501516-treated PPAR-␦ KO mouse EPCs ( Figure IVC to IVE in the online-only Data Supplement), suggesting that GW501516 exerts its provasculogenic effect through PPAR-␦.
Systemic Administration of PPAR-␦ Agonist Enhances EPC Mobilization and Vasculogenesis at the Injured Cornea of Mice That Received BM Transplantation From Green Fluorescent Protein-Transgenic Mice
To determine whether systemic PPAR-␦ activation actually increases the number of EPCs in vivo, we counted EPCs in the peripheral blood as well as multipotent hematopoietic stem cells (HSCs) in BM after systemic administration of GW501516. Mice were treated with GW501516 or vehicle for 14 days (nϭ6 in each group), and then BM and whole peripheral blood were obtained. The percentage of multipotent HSCs, as represented by the coexpression of c-kit and sca-1, was found to be significantly higher in the BM of the GW501516-treated mice (percentage of c-kit/sca-1 doublepositive cells: 0.17Ϯ0.11% versus 0.43Ϯ0.15% for control group versus GW501516-treated group) ( Figure 6A ).
After 8 days of peripheral MNC culture, EPCs were confirmed by a combination of DiI-labeled acetylated lowdensity lipoprotein (DiI-acLDL) uptake and Bandeiraea simplicifolia (BS)-1 lectin binding. The number of EPCs from the peripheral blood was significantly higher in the GW501516-treated group (relative percentage to control [100%]: 233.9Ϯ39.6% for GW501516-treated group) ( Figure  6B, 6C) .
To establish whether these EPC mobilization effects of systemic PPAR-␦ activation were actually associated with augmented vasculogenesis, the effects of GW501516 therapy on new vessel formation were tested in a murine model of corneal neovascularization after BM transplantation. WT mice received BM transplantation from donor green fluorescent protein (GFP)-transgenic mice. After completing a 14-day course of GW501516 or control vehicle administration, transplanted mice underwent corneal microsurgery (nϭ5 in each group). The corneas of mice were harvested at 6 days after surgery. During these 6 days, GW501516 or vehicle administration was maintained. GW501516 therapy resulted in enhanced corneal neovascularization ( Figure 7A ). Quantitative analysis showed that GW501516 increased both the length and number of microvessels from limbal arteries in injured corneas (length, 0.32Ϯ0.05 mm in control group, 0.55Ϯ0.05 mm in GW501516-treated group; number, 4Ϯ1 in control group, 12Ϯ3 in GW501516-treated group) ( Figure  7B ). In vivo fluorescence staining of corneas with BS-1 lectin showed greater neovascularization and more extensive incorporation of BM-derived GFP-positive cells in the GW501516 group ( Figure 7C ).
Systemic Administration of PPAR-␦ Agonist Enhances Vasculogenesis in Mouse Ischemic Hindlimb
In the aforementioned experiments, PPAR-␦ activation in EPCs before transplantation resulted in the enhancement of vasculogenic potential of EPCs for ischemic limb. Then we assessed the effects of systemic PPAR-␦ activation on the vasculogenesis in the mouse ischemic hindlimb model. After a 3-day course of intraperitoneal administration of GW501516 or vehicle, C57BL/6 mice underwent unilateral femoral artery excision (nϭ10 in each group). GW501516 or vehicle therapy was maintained for 21 days after surgery. Serial follow-up with the use of a laser Doppler perfusion imager showed better blood flow to the ischemic limb in the mice injected with GW501516 ( Figure 8A, 8B) . At day 21 after surgery with systemic PPAR-␦ activation, capillary density of ischemic limb was significantly higher in the GW501516-treated mice (capillary density, 795.9Ϯ149.7/ mm 2 versus 452.4Ϯ97.9/mm 2 for GW501516-treated group versus control group) ( Figure 8C, 8D) . Confocal microscopic examination of CD31-immunofluorescent staining of thick cryosections demonstrated a robust vasculogenesis in the ischemic limb of GW501516-treated mice ( Figure 8E ).
Discussion
Since Asahara and colleagues 1 reported the presence of EPCs in the adult peripheral blood in 1997, many researchers have focused interest on EPC biology and its clinical application. Although the therapeutic potential of EPCs in treating ischemic vascular disease seems promising, its application is hindered by the limited number of available EPCs. Thus, efforts to modulate EPCs with drugs 24, 25 or by genetic modifications 29, 30 are under intense study.
PPAR-␦ is expressed in diverse tissues and cells, 3, 7, 26 but its function outside the metabolic effects is poorly understood. Its reported roles in vascular biology include the induction of EC proliferation, 8, 9 angiogenesis, 9 and EC protection from H 2 O 2 -induced apoptosis. 10 Our experiments provide the first evidence that PPAR-␦ activation has a provasculogenic effect both in vitro and in vivo. We found that PPAR-␦ activation increased the proliferation of EPCs and protected them from apoptosis. Moreover, PPAR-␦ activation significantly enhanced EPC functions. Then the in vivo provasculogenic effects of PPAR-␦ activation were confirmed in 2 different aspects. First, in the mouse ischemic hindlimb model, we showed that local delivery of ex vivo PPAR-␦-activated EPCs significantly enhanced new vessel formation, resulting in better limb perfusion. The PPAR-␦ specificity of these beneficial effects was confirmed by PPAR-␦ KO mice. These results suggest that the clinical impact of local delivery of EPCs modulated with PPAR-␦ agonist is great compared with naive EPCs that have been used in clinical trials. Second, the systemic effects of PPAR-␦ agonist were also studied. Systemic administration of PPAR-␦ agonist significantly increased the number of HSCs in BM, leading to EPC mobilization. These effects resulted in improved vasculogenesis in a corneal neovascularization model and limb salvage with better blood flow in an ischemic hindlimb model. These results indicate that the systemic administration of PPAR-␦ agonist by itself has therapeutic potential.
Other interesting and novel findings of the present study are that the beneficial effects observed with PPAR-␦ activation in EPCs are mediated by the PI3K/Akt pathway, a key pathway that mediates vasculogenesis. [23] [24] [25] In our study, GW501516 also activated the PI3K/Akt pathway, suggesting that PPAR-␦ agonist may be yet another drug that can target the activation of the PI3K/Akt signaling pathway in EPCs. The activation of the PI3K/Akt pathway by PPAR-␦ activation has been reported previously in other cell types such as keratinocytes 14 and lung cancer cell lines, 15 but this is a novel finding in EPCs. In keratinocytes, PPAR-␦ modulates Akt phosphorylation via transcriptional upregulation of integrinlinked kinase. 14 However, in our Western blot assay, there was no change in integrin-linked kinase up to 24 hours after GW501516 treatment (data not shown). The specificity and potency of activation of genomic target genes by PPARs are known to be highly dependent on the cell type, 31 which might explain the observed difference in integrin-linked kinase production.
We also first showed that PPAR-␦ activation led to the phosphorylation of Akt via not only the genomic pathway but also the nongenomic pathway. We found another peak of Akt phosphorylation as early as 10 minutes after PPAR-␦ activation, and this could not be inhibited by actinomycin D treatment, suggesting that such an effect is not dependent on transcription and is thus a nongenomic effect. Glucocorticoids and estrogen are known to nontranscriptionally activate the PI3K/Akt pathway in ECs. 19, 20 This activation arises within minutes and is not blocked by actinomycin D. The nontranscriptional activation in cytoplasm was shown to be a result of interaction in the cytoplasm between the glucocorticoid receptor or estrogen receptor and p85␣, a regulatory subunit of PI3K. 19, 20 Glucocorticoid receptor and estrogen receptor are members of the nuclear hormone receptor superfamily similar to PPAR-␦, and these receptors have a conserved domain structure. 32 Therefore, we hypothesized that PPAR-␦ might activate PI3K nontranscriptionally by the same mechanism. Indeed, we showed by immunoprecipitation that the agonist increased PPAR-␦ binding with p85␣ in the early period.
Several effects of "PPAR-␥ agonists," the most extensively studied PPAR subtype, have been shown to be PPAR-␥ independent. 16, 17 However, in the present study, 2 different PPAR-␦ agonists (ie, GW501516, L-165041) exerted the same in vitro effects on EPCs, confirming that these effects are PPAR-␦ dependent. Furthermore, EPCs from PPAR-␦ KO mice did not show in vivo provasculogenic effects after GW501516 treatment in contrast to those from WT mice. Moreover, the genomic and nongenomic activation of the PI3K/Akt pathway by GW501516 was dependent on PPAR-␦, as verified by an antisense oligodeoxynucleotide transfection assay. Therefore, we concluded that the results in this study are dependent on PPAR-␦.
Three different processes of vascular growth exist. Vasculogenesis describes the formation of blood vessels from EPCs. Angiogenesis denotes the sprouting of capillaries from preexisting ECs. The growth and remodeling of a collateral artery is termed arteriogenesis. 33, 34 In an ischemic hindlimb model, arteriogenesis is known to occur mainly in the upper part of the limb; on the contrary, angiogenesis and vasculogenesis are driven by tissue ischemia in the lower part. 34 The greater vascular incorporation of BM-derived cells by PPAR-␦ agonist in a corneal injury model suggests that vasculogenesis may at least work in perfusion improvement by PPAR-␦ agonist in our hindlimb ischemia models. EPCs may also induce angiogenesis and arteriogenesis in ischemic limb through a paracrine effect. 35 The discussion of the exact proportion of contributions from these different processes to the recovery of limb perfusion is not within the scope of this study and may require further study.
In conclusion, our data suggest that PPAR-␦ agonist enhances vasculogenesis and may be a novel therapeutic option to modulate EPCs in the treatment of ischemic vascular diseases.
